News
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...
3d
ScienceAlert on MSNOzempic-Like Drugs Could Treat Chronic Migraines, Trial FindsMedications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...
13d
Everyday Health on MSNCould One of These Drugs Be the Next Ozempic?The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...
A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
The UK’s drug regulator is to study possible serious side effects of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Data from ...
The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...
Medical Xpress on MSN13d
From blood sugar to brain relief: GLP-1 therapy slashes migraine frequencyA diabetes medication that lowers brain fluid pressure has ... Headache Centre of the University of Naples “Federico II” gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 ...
China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results